| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | Y | Z | AA | AB | AC | AF | AG | AH | AI | AJ | AK | AL | AM | AN | AO | AP | AQ | AR | AS | AT | AU | AV | AW | AX | AY | AZ | BA | BB | BC | BD | BE | BF | BG | BH | BI | BJ | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | [how to sort/filter] [* = see notes col] [gray = older info] | is it aging? | aging mission? | core aging area? | multiple aging diseases? | core aging confs? | is it rejuvenation? | operating status | short summary (intended to be objective, usually from company website, edited for brevity) | clinical stage (& link to pipeline) | pipeline image [if not clickable, use clin stage link] | Tx or Dx | categories (map to SENS & hallmarks) | diseases/ indications [not comprehensive or canonicalized] | species (beside humans) | clinical trials | targets / pathway / MoAs | modalities | regulatory category | team | geo(s) | public? | ticker Y! | market cap (M) | employees, Y! publics | employees LI | year founded | tot. raised (US$M) | raised other curr | pharma partners/ investors | product names | pubs/ papers | as of (last full row update) | date added to list | notes | full overall score | score w/o 4p focus | aging focus score | 4-prong focus score (confs wght less) | operating status score | pipeline image bonus | clin. stage score | # employees score | total raised / valuation score | Tx > Dx | pharma > supplements / unreg | pubs bonus | check for all 4 no | updated since Jul 2024? | |||||||||||
2 | Calico | yes | yes | yes | yes | yes | operating | broad mission to improve health and longevity using technology to advance biological science | ph.2/3 trials (full list of trials) | Tx | big industrial R&D | ALS, cancer, vanishing white matter | 10 | eIF2B | pharma | Arthur D. Levinson, Cynthia Kenyon | SF | no | 363 | 2013 | $2,500 | Abbvie | many | 2024-07-25 | 2019 | 17 PIs listed as of Jul'24. Initially funded/created within Google/Alphabet. | 13.0 | 13.0 | 1.0 | 1.0 | 1.0 | 1.0 | 2.3 | 3.7 | 4.9 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||
3 | Stealth BioTherapeutics | yes | yes | yes | yes | no | no | operating | mitochondria platform for age & genetic mito diseases; first a peptide to stabilize inner mito membrane | ph.3 trials |  | Tx | mitochondria | AMD, DMD, ALS, mito-neuroDs | 29 | cardiolipin | peptides, small molecules | pharma | Reenie McCarthy | Boston | no* | 66 | 2007 | $191 | Elamipretide | several publications | 2024-07-16 | 2019 | *Was public, but taken private in 2022. | 9.9 | 11.0 | 1.0 | 0.9 | 1.0 | 1.1 | 3.3 | 2.6 | 3.3 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||
4 | Altos Labs | yes | yes | yes | yes* | yes | yes | operating | cell rejuvenation by partial/epigenetic reprogramming; big & academic-like: aiming to be "Bell Labs" of bio | pre-clinical | Tx, Dx | epigenetic, big industrial R&D | OSKM | pharma | Hal Barron, Rick Klausner, Hans Bishop, Juan Carlos I. Belmonte, Wolf Reik, Jodi Nunnari | SF; SD; Cambridge, UK | no | 527 | 2021 | $5,560 | 2024-07-12 | 2022-06-19 | *Diseases not specified but mission clearly includes multiple age-related diseases. 22 PIs listed as of Jul'24. Jul'24 Rick Klausner said they extended old mice lifespan 25% w/ 1 injection of Yamanaka formulation in a 1000 mouse study. Jeff Bezos widely reputed to be an investor. | 9.8 | 9.8 | 1.0 | 1.0 | 1.0 | 1.0 | 0.5 | 3.9 | 5.4 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||||
5 | BioAge Labs | yes | yes | yes | yes | yes | no | operating | human long-term biobanks + multiomics + AI drug platform for metabolic aging w/ APJ & NLRP3 leads | ph.2 trials |  | Tx | metabolism, inflammation | obesity, muscle atrophy, neuroinflam | 4 | APJ, NLRP3 | drugs | pharma | Kristen Fortney, Eric Morgen, Paul Rubin | SF | yes | BIOA | $162 | 58 | 87 | 2015 | $294 | Lilly* | main pubs; paper | 2024-07-12 | 2019 | Lead APJ/apelin program now listed as being for obesity (arguably not age related) but previously described as being for muscle atrophy which is age-related & APJ clearly related to core aging pathways. *Partnered with Lilly for the obesity phase 2 trial & Lilly participated in the early 2024 $170M series D round. | 9.8 | 9.8 | 1.0 | 1.0 | 1.0 | 1.1 | 2.2 | 2.8 | 3.2 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||
6 | Juvenescence | yes | yes | yes | yes | yes | operating | umbrella company focused on aging w/ both (ketone) supplement & pharma programs (PAI-1, GDF15, CD38, ketones, & plasmalogens, autophagy, liver & limb regen) | commercial, ph.2a trials* |  | Tx | umbrella company | fibrosis, muscle wasting in cancer, RA, HF, dementia | 2 | PAI-1, GDF15, CD38, plasmalogens | drugs & others, supplement | pharma, nutraceuticals | Richard Marshall, Greg Bailey, Jim Mellon | London, NYC | no | 28 | 2016 | $308 | papers | 2024-07-27 | 2019 | *Subco LyGenesis in ph.2a; in-house program in ph.1 as of Dec'24. Portfolio companies include BHB Therapeutics, BOPZ Nutrition, Chrysea, LyGenesis, Morphoceuticals, Relation Therapeutics, & Souvien Therapeutics. | 8.5 | 8.5 | 1.0 | 1.0 | 1.0 | 1.1 | 1.5 | 2.1 | 3.6 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
7 | Mesoblast | yes | no | yes | yes* | no | yes | operating | allogeneic mesenchymal stem cells for multiple (esp inflammatory) diseases | approved (ph.3 success)* |  | Tx | stem cells / allogeneic | HF, deg-discD, Covid (& non-agingDs) | 42 | MSCs | cell therapy | pharma | Silviu Itescu | NYC, Melbourne | yes | MESO | $2,140 | 83 | 77 | 2004 | $452 | Revascor, Ryoncil (Remestemcel-L) | many | 2024-07-12 | 2019 | *Focus on non-age-related conditions too, but stem-cells clearly applicable to aging diseases too & multiple unrelated aging diseases in their pipeline. With partners they've received approval for some treatments in Japan & Europe for non-aging diseases. Jul'24 BLA submitted to FDA for pediatric steroid-refractory acute graft versus host disease (SR-aGVHD), a notable regulatory step even if not primarily age-related. | 8.5 | 14.2 | 1.0 | 0.6 | 1.0 | 1.1 | 4.4 | 2.7 | 4.8 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||
8 | Scholar Rock | yes | no | yes | yes | no | no | operating | platform for targeting precursors of growth factors including myostatin & TGFβ | ph.3 trials |  | Tx | metabolism, inflammation, cancer | muscle atrophy, cardiometabolic, cancer, fibrosis | 6 | myostatin, TGFβ | monoclonal antibodies | pharma | Jay Backstrom | Boston | yes | SRRK | $3,680 | 150 | 174 | 2012 | $443 | Apitegromab | papers & posters | 2024-07-14 | 2022-06-28 | Named after scholar rocks, unusual rocks appreciated by scholars in east Asia (esp China) for their unusual & intricate shapes that resemble protein shapes. | 8.4 | 13.9 | 1.0 | 0.6 | 1.0 | 1.1 | 3.3 | 3.2 | 5.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||
9 | Celularity | yes | yes | yes | yes | no | yes | operating | allogeneic placental-derived cell therapies (MLASCs, CAR-T, NK cells) for aging, degenerative, immune diseases, cancer; also biomaterials | ph.1/2 trials |  | Tx | stem cells / allogeneic, senescence | cancer, muscleDs, autoimmuneDs | 17 | MLASCs, CAR-T, NK cells | cell therapy | pharma | Robert Hariri | NYC | yes | CELU | $59 | 255 | 172 | 2016 | $400 | posters in sub pages | 2024-07-28 | 2019 | Added a senolytic program (based on NK cells) relatively recently (as of 2024). Also run income generating programs to bank placental stem cells and to treat burns & wounds, with projected $40M revenue, as of 2019. | 7.8 | 8.7 | 1.0 | 0.9 | 1.0 | 1.1 | 1.5 | 3.2 | 2.5 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||
10 | Alkahest (owned by Grifols) | yes | yes | yes | yes | yes | yes | acquired*, operating independly | leads from blood proteins that go up or down with age, eg young blood fractions | ph.2 trials |  | Tx | cell communication | AD, PD, wAMD, ESRD MCI | 13 | drugs, biologics, blood fractions | pharma | Esther Rawner, Tony Wyss-Coray | SF | public owner | $265 | 59 | 2014 | $50 | Grifols | papers | 2024-07-26 | 2019 | *Aquired by Grifols (remaining 55% for $146M) Sep'20, but website still operating indepedently. | 7.4 | 7.4 | 1.0 | 1.0 | 0.8 | 1.1 | 2.2 | 2.5 | 3.5 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||
11 | Immunis Inc. | yes | yes | yes | yes | yes | yes | operating | stem-cell secretome products for age-driven immune dysfunction, muscle regeneration & metabolism | ph.2 trials |  | Tx | stem cells | muscle atrophy, woulds, metadb, neuroDs, immuneDs | 3 | secretome cocktail | pharma | Hans Keirstead | LA | no | 17 | 2018 | $32 | IMMUNA | 2024, 2021 papers | 2024-08-18 | 2023-01-24 | Not to be confused with Immunis.AI. | 7.4 | 7.4 | 1.0 | 1.0 | 1.0 | 1.1 | 2.2 | 1.8 | 2.2 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||
12 | Juvena Therapeutics | yes | yes | yes | yes | yes | yes | operating | computationally-driven platform based on human stem cell secreted proteins engineered into novel biologics | ph.1 trials |  | Tx | stem cells, cell communication | DM1, obesity, fibrosis, OA | 1 | biologics | pharma | Hanadie Yousef, Jeremy O'Connell | SF | no | 43 | 2017 | $49.2 | click pubs | 2024-08-04 | 2019 | 7.0 | 7.0 | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 | 2.3 | 2.4 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||
13 | Biosplice (was Samumed) | yes | no | yes | yes | no | yes | operating | alt splicing by targeting CLK/DYRK kinases w/ small molecules (came to this via work on Wnt pathway) to eliminate harmful proteins, 1st for OA, onco, neuro | ph.3 trials |  | Tx | splicing, proteostasis? | OA, deg-discD, cancer, AD, TBI, tauDs | 22 | CLK/DYRK family kinases | small molecules | pharma | Cevdet Samikoglu | SD | no | 42 | 2008 | $778 | Lorecivivint, Cirtuvivint | several | 2024-07-15 | 2019 | Formerly called Samumed. | 7.0 | 11.7 | 1.0 | 0.6 | 1.0 | 1.1 | 3.3 | 2.3 | 4.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||
14 | Life Biosciences | yes | yes | yes | yes | yes | yes | operating | epigenetic reprogramming via OSK and small molecules for chaperone mediated autophagy | pre-clinical |  | Tx | epigenetic, autophagy | eyeDs, neuroDs | OSK, LAMP2A | gene therapy, small molecules | pharma | David Sinclair, Jerry McLaughlin | Boston | no | 22 | 2017 | $207 | papers | 2024-08-04 | 2019 | Originally an umbrella company focused on aging with many notable professors in the field involved. | 6.9 | 6.9 | 1.0 | 1.0 | 1.0 | 1.1 | 0.6 | 1.9 | 3.3 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
15 | Cambrian Bio | yes | yes | yes | yes | yes | operating | umbrella company focused on aging w/ leads in AMPK, mitochondria, mTOR, & more. | ph.1b trials* |  | Tx | umbrella company | cardiometabolic, cancer | 0* | AMPK, mTOR | drugs | pharma | James Peyer | NYC | no | 32 | 2019 | $160 | 2024-07-13 | 2020-05-03 | *Pipeline image shows ph.1/2a for ATX-304 & Amplifier website pipeline shows just ph.2 but can't find trial on clinicaltrials.gov under either company name or ATX-304 as of Jul'24 so using press release of 1b. Portfolio companies include: Amplifier Tx, Isterian, Oviva Tx, Telos Bio, Tornado Tx, & Vita Tx. | 6.4 | 6.4 | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 | 2.2 | 3.2 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||
16 | Retro Biosciences | yes | yes | yes | yes | yes | yes | operating | HSC reprogramming, autophagy enhancement, & apheresis-inspired microglia therapeutics w/ goal to extend healthspan 10yrs | pre-clinical |  | Tx | epigenetic, autophagy, stem cells | AD, OA, hearing loss | small molecules, stem cells, TFs | pharma | Joe Betts-LaCroix | SF | no | 57 | 2021 | $180 | 2024-08-01 | 2021-05-11 | 6.3 | 6.3 | 1.0 | 1.0 | 1.0 | 1.1 | 0.6 | 2.5 | 3.2 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||
17 | Rubedo Life Sciences | yes | yes | yes | yes | yes | yes | operating | target pathological cells that drive aging, esp senescent cells, using AI, single cell seq, & precision targeting through computational drug design inc pro-drugs | pre-clinical |  | Tx | senescence | AD, psoriosis, IPF, NASH, cancer, sclerosis | GPX4 | small molecules | pharma | Marco Quarta | SF | no | 28 | 2018 | $54 | papers | 2024-08-06 | 2019 | Announced strategy multi-year partnership with skin care giant Beiersdorf, to develop aging skin products esp senolytics, Apr'24. | 6.1 | 6.1 | 1.0 | 1.0 | 1.0 | 1.1 | 0.6 | 2.1 | 2.5 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
18 | Turn Biotechnologies | yes | yes | yes | yes | yes | yes | operating | mRNA epigenetic reprogramming to restore capabilities lost with age via OSKMLN | pre-clinical |  | Tx | epigenetic | skin conditions, OA, glaucoma, frailty/sarcopenia | OSKMLN | RNA | pharma | Anja Krammer, Vittorio Sebastiano | SF | no | 33 | 2018 | $30.1 | key paper* | 2024-08-10 | 2019 | *OSKMLN shown to reverse 8 of the 9 hallmarks of aging, all except telomeres. | 5.8 | 5.8 | 1.0 | 1.0 | 1.0 | 1.1 | 0.6 | 2.2 | 2.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
19 | Gero | yes | yes | yes | yes | yes | operating | physics / dynamical systems based modeling of aging via deep nets AI on whole-exome sequencing & digital biomarkers licensing/partnering & AI drug development | pre-clinical |  | Tx, Dx | CVD, cancer, fibroticDs | drugs | pharma | Peter Fedichev | no | 132 | 2018 | $6 | Pfizer | papers | 2024-08-15 | 2019 | 5.8 | 5.8 | 1.0 | 1.0 | 1.0 | 1.1 | 0.6 | 3.0 | 1.2 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||||
20 | Alnylam | borderline* | no | yes | yes | no | no | operating | general platform to develop RNA interference (RNAi) therapieus to silence disease-specific genes, with broad application to many age-related disease areas | approved (ph.3 success) |  | Tx | proteostasis | (h)ATTR(-CM), AD, HD, ALS, T2D, MASH, NAFLD, hypercholesterolemia, hypertension | 82 | ATTR, APP, PCSK9, AGT, HTT, SOD-1, HSD17B13 | siRNA | pharma | Yvonne Greenstreet, Kevin Fitzgerald | Boston | no | ALNY | $40,566 | 2100 | 2442 | 2002 | >$100M | Onpattro, Amvuttra, Leqvio | science presentations | 2025-02-02 | 2024-08-15 | *Borderline: Broad product pipeline & mission of RNAi therapeutics makes it more like a modality-themed generic med-to-big pharma rather than aging company, but pipeline includes majority age-related diseases with tx for several misfolded proteins (ATTR, AD, HD, ALS) & multiple CVD related diseases (ATTR, hypercholesterolemia, & hypertension) plus misc age-related liver/metabolic (MASH, T2D, NAFLD). | 5.7 | 9.5 | 0.5 | 0.6 | 1.0 | 1.1 | 4.4 | 4.8 | 6.6 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||
21 | Elevian | yes | yes | yes | yes | yes | operating | recombinant GDF11, first for stroke | pre-clinical |  | Tx | cell communication | stroke, pancreatitis, wound healing, cardiometabolicDs | GDF11 | biologics | pharma | Mark Allen | Boston | no | 11 | 2017 | $64 | bottom of page | 2024-08-12 | 2019 | 5.6 | 5.6 | 1.0 | 1.0 | 1.0 | 1.1 | 0.6 | 1.5 | 2.6 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||
22 | Attralus | yes | no | yes | yes | no | yes | operating | pan-amalyoid diagnostics & therapeutics for amyloid diseases: systemic amyloidosis (ATTR & AL) & neurodegenerative diseases w/ misfolded proteins | ph.2 trials |  | Tx, Dx | proteostasis | systemic amyloidosis, AD, PD | 3 | ATTR, AL, Aβ, Tau, α-synuclein | peptides | pharma, reg Dx | Mark Timney | SF | no | 31 | 2019 | $198 | posters & pubs | 2024-10-19 | 2020-01-04 | Formerly called Aurora Bio (not to be confused with several other companies called Aurora Bio: Sydney based medical device maker Aurora BioScience, cancer company Aurora BioPharma, drug discovery system company Aurora Biosciences, acquired by Vertex in 2001). | 5.5 | 9.1 | 1.0 | 0.6 | 1.0 | 1.1 | 2.2 | 2.1 | 3.3 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||
23 | Longeveron | yes | yes | yes | yes | no | yes | operating | allogeneic mesenchymal stem cells f/ bone marrow | ph.2 trials |  | Tx | stem cells / allogeneic, mitochondria* | frailty, AD, metabolicDs, ARDS, HLHS | 10 | MSCs | cell therapy | pharma | Wa’el Hashad, Joshua Hare | Miami | yes | LGVN | $22 | 23 | 26 | 2014 | $34.0 | Lomecel-B | 2024-07-28 | 2019 | *Primarily stem cells, but MoA page notes that mitochondrial transfer (transplant) is one of the MoAs (injected SCs donate mitochondria). Lomecel-B got RMAT designation from FDA (first cell therapy to get this for AD) as of Jul'24. | 5.6 | 6.2 | 1.0 | 0.9 | 1.0 | 1.1 | 2.2 | 2.0 | 1.9 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||
24 | Athersys Inc | yes | no | yes | yes | no | yes | operating | allogeneic stem cells | ph.3 trials (completed in Japan) |  | Tx | stem cells / allogeneic | stroke, ARDS, trauma, neuroDs, CVD, lungDs | 4 | cell therapy | pharma | Daniel Camardo | Cleveland, OH | no* | 37 | 1995 | $209 | MultiStem | 2024-08-01 | 2019 | *Was public but delisted in 2023. RMAT designation in stroke. | 5.3 | 8.9 | 1.0 | 0.6 | 1.0 | 1.1 | 3.3 | 2.2 | 3.3 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||
25 | Centara Labs (was Rejuveron) | yes | yes | yes | yes | operating | umbrella company focused on aging | ph.2a trials* |  | Tx | umbrella company | RP, dAMD, cancer, sacropenia, IPF, neuroDs | 0 | pharma | Aksana Labokha, Christian Angermayer | Zurich | no | 14 | 2019 | $86 | 2024-08-02 | 2021-05-06 | *Endogena pipeline says 2a trials as of Aug'24. Portfolio companies include Endogena, Rejuvenate Biomed, Rejuveron Senescence Tx, Rejuveron Telomere Tx, Rejuveron Vascular Tx, Boost Neuro. | 5.3 | 5.9 | 1.0 | 0.9 | 1.0 | 1.1 | 1.5 | 1.6 | 2.8 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||||
26 | Rejuvenate Biomed | yes | yes | yes | yes | no | no | operating | platform for finding synergistic combinations of existing approved drugs for age-related diseases, lead combines metformin & galantamine (an AD drug) | ph.1 trials* |  | Tx | broad platform, metabolism, inflammation | sarcopenia, OA | 0 | AMPK, AChE | small molecules | pharma / existing combos | Ann Beliën | Belgium | no | 14 | 2017 | $23 | 1 paper for lead | 2024-09-04 | 2023-05-29 | *Pipeline diagram makes it look like its in phase 2 already, but can't find the trials on clinicaltrials.gov site. Rejuveron sub-company. Not to be confused with Rejuvenate Bio. | 5.1 | 5.6 | 1.0 | 0.9 | 1.0 | 1.1 | 1.1 | 1.6 | 2.0 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||
27 | Vaxxinity (website removed all info intentionally*) | yes | yes | yes | no | operating* | synthetic peptide vaccines for chronic diseases inc. AD, PD, migraine, & hypercholesterolemia (& infections inc Covid) | ph.3 trials | Tx | proteostasis | AD, PD, CVD, Covid | 9 | Aβ, α-synuclein, cholesterol | peptide vaccine | pharma | Florida, NYC | no* | 63 | 2014 | $9.3 | paper; old paper | 2024-08-04 | 2019 | *Was public (ticker VAXX) but voluntarily delisted May'24 & removed all info from main website as of Aug'24 (says it's gone dark, but still there), but investor relations website still has info at ir.vaxxinity.com inc. press releases thru Jun'24. FAQ about delisting explains rationale for not reporting public co info but not for website showing less info than a pre-public co. Formerly called United Neuroscience. | 5.1 | 8.4 | 1.0 | 0.6 | 1.0 | 1.0 | 3.0 | 2.6 | 1.4 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||||
28 | OrsoBio | yes | no | yes | yes | no | no | operating | restore energy homeostasis for metabolic disorders via regulating lipid biogenesis & mitochondria entry, mito protonophores (uncoupling), & ↑ NAD+ synthesis | ph.2 trials* |  | Tx | metabolism, mitochondria | obesity, T2D, NASH, hypertriglyceridemia | 4 | ACC2, LXR, ACMSD | small molecules | pharma | Mani Subramanian | SF | no | 17 | 2021 | $129 | papers | 2024-09-11 | 2024-09-11 | *Pipeline diagram shows phase1, but science page & clinical trials show phase 2, as of Sep'24. | 5.0 | 8.4 | 1.0 | 0.6 | 1.0 | 1.1 | 2.2 | 1.8 | 3.0 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||
29 | Aeovian | yes | yes | yes | yes | no | no | operating | selective mTORC1 inhibitors & (mostly CNS penetrant) inhibitors of CD38 (which degrades NAD+) | ph.1 trials |  | Tx | metabolism / mTOR, mitochondria / NAD+ | epilepsy, neuroDs, metabolicDs | 1 | mTOR, CD38 | small molecules | pharma | SF | no | 10 | 2012 | $87 | 2024-07-27 | 2019 | Mar'24 raised $50M led by Hevolution (first public Hevolution lead investment). Formerly called Aeonian. | 4.8 | 5.3 | 1.0 | 0.9 | 1.0 | 1.1 | 1.1 | 1.4 | 2.8 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||
30 | Ichor Life Sciences | yes | yes | yes | yes | yes | yes | operating | CRO & umbrella company focused on aging | commercial, pre-clinical | Tx | CRO, umbrella company, intracell junk | AMD | small molecules, biologics | pharma | Kelsey Moody | Syracuse, NY | no | 38 | 2013 | $4.5 | several | 2024-08-03 | 2019 | 2021: shifted to focus on service (CRO) offerings rather than being primarily an umbrella development company (previously called Ichor Therapeutics), but still has an aging emphasis & portfolio of sub-companies. Portfolio companies include: LysoClear, MitoChem, Auctus Bio, & Lento Bio. | 4.6 | 4.6 | 1.0 | 1.0 | 1.0 | 1.0 | 0.5 | 2.3 | 1.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||
31 | Olatec | yes | no | yes | yes | no | no | operating | oral small molecule NLRP3 inhibitor that lowers inflammation via effects on IL‑1β & IL-18, with some advantages over directly targeting those | ph.2/3 trials | Tx | inflammation | gout flare, cancer, T2D, PD, HF, OA | 10 | NLRP3 | small molecules | pharma | Damaris B. Skouras | NYC, Boston | no | 15 | 2003 | $40 | dapansutrile | papers | 2024-11-23 | 2024-08-15 | 4.6 | 7.6 | 1.0 | 0.6 | 1.0 | 1.0 | 2.3 | 1.7 | 2.3 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
32 | Gordian Biotechnology | yes | yes | yes | yes | operating | mosaic (pooled in vivo) screening in animals best representing target diseases w/ full transcriptome AI analysis | pre-clinical | Tx | broad platform | gene therapy | pharma | Francisco LePort, Martin Borch Jensen | SF | no | 37 | 2018 | $60 | a few papers + talks | 2024-08-01 | 2019 | Not to be confused with several other companies named Gordian, in IT, investment banking, & staffing/recruiting. | 4.5 | 6.4 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 2.2 | 2.6 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||||||
33 | Biophytis | yes | yes | yes | no | operating | drug discovery platform for aging & degenerative conditions based on discovery from plant secondary metabolites, mostly via MoAs that increase resilience | ph.3 trials* |  | Tx | broad platform | sarcopenia, dAMD, MD, obesity, Covid | 3 | MasR | small molecules | pharma | Stanislas Veillet | Paris | yes | ALBPS.PA | $3 | 22 | 25 | 2006 | $37 | Ruvembri, Sarconeos,Macuneos | sarcopenia; eye | 2024-07-28 | 2019 | *Phase 3 Covid trial seems to have succeeded based on this press release. Pipeline diagram makes it look like regulatory approval is in progress. | 4.5 | 7.4 | 1.0 | 0.6 | 1.0 | 1.1 | 3.3 | 2.0 | 0.9 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||
34 | Loyal | yes | yes | yes | yes | yes | no | operating | drug(s) to treat aging in dogs, by lowering IGF-1 & other metabolism interventions | vet clinical trials | Tx | metabolism | dogs | IGF-1 | drugs | veterinary | Celine Halioua | SF | no | 64 | 2019 | $150 | near page bottom | 2024-07-13 | 2019-12-19 | The company got the FDA to formally accept a clinical trial design using lifespan as an endpoint, a significant regulatory hurdle for the field. | 4.3 | 4.3 | 1.0 | 1.0 | 1.0 | 1.0 | 1.5 | 2.6 | 3.1 | 1.0 | 0.5 | 1.2 | 0 | 1 | ||||||||||||||||||||
35 | Mitotech | yes | yes | yes | yes | yes | no | operating | mito-targeted small molecules for oxidative stress & lipid peroxidation (cardiolipin peroxidation inhibitors), 1st for eye diseases then neuro & metabolic conditions | ph.3 trials | Tx | mitochondria | dAMD, other eye diseases, later AD, PD, ALS, NASH | 3 | cardiolipin | small molecules | pharma | Natalia Perekhvatova | Russia | no | 8 | 2009 | unknown | Visomitin, SkQ1 | 2024-09-03 | 2022-06-20 | 4.3 | 4.3 | 1.0 | 1.0 | 1.0 | 1.0 | 3.0 | 1.3 | 0.0 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||
36 | Oisin Biotechnologies | yes | yes | yes | yes | yes | yes | operating | repeat doseable genetic medicines (DNA or RNA) for aging (frailty via muscle, kill fat cells & senescent cells) via non-viral gene therapy w/ good non-liver distribution | pre-clinical | Tx | senescence, genomic | frailty, obesity, cancer | follistatin, fat cells, p16, p53 | gene therapy / non-viral | pharma | Matthew Scholz, John Lewis | SF, Seattle, SD | no | 17 | 2014 | $25 | 2024-08-05 | 2019 | First close of $15M series A announced Jul'2024. Spun out OncoSenX for cancer (not on this list since devoted only to cancer, but for the purposes of this list the 2 companies are best considered as one). Uses Entos Pharma's non-viral gene therapy delivery platform. | 4.3 | 4.3 | 1.0 | 1.0 | 1.0 | 1.0 | 0.5 | 1.8 | 2.0 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||
37 | Alchemab Therapeutics | yes* | no | yes | yes | no | operating | drug discovery platform based on sequencing B cells of long-term survivors, understanding the antibody targets & feeding that into a comput. drug discovery engine | pre-clinical |  | Tx | broad platform | FTD, ALS, AD, Huntington's, cancer** | CD33, Huntingtin, Complement Factor H | antibodies | pharma | Young Kwon | Cambridge, UK | no | 62 | 2019 | $86 | check box for pubs | 2024-08-02 | 2021-05-11 | *See this piece for discussion of the platform's relationship to longevity. **Besides pipeline indicationts, also has samples for ALS, more cancers, Covid, & centenarians. | 4.2 | 7.1 | 1.0 | 0.6 | 1.0 | 1.1 | 0.6 | 2.6 | 2.8 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||
38 | Denali Therapeutics | only neuro* | no* | yes | yes | no | operating | drug discovery for neurodegeneration, optimized for brain delivery, guided by genetics & biomarkers, but also lysosomal storage disesaes & systemic inflam. | ph.3 trials |  | Tx | autophagy, inflammation | PD, FTD, Hunter's, ALS, AD, MS, inflammation | 22 | eIF2B, iduronate 2-sulfatase, LRRK2, progranulin, sulfamidase, alpha-L-iduronidase | small molecules, biologics | pharma | Ryan Watts | SF | yes | DNLI | $2,059 | 375 | 422 | 2015 | $1,100 | papers | 2024-08-01 | 2019 | *Mission is neurodegeneration & lysosomal storage diseases. They also have a program on systemic inflammation, but almost all indication are neuro. | 4.2 | 7.1 | 0.5 | 0.6 | 1.0 | 1.1 | 3.3 | 3.8 | 4.7 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||
39 | Blue Rock Therapeutics (owned by Bayer) | yes | no | yes | yes | no | yes | acquired*, operating independ. | universal pluripotent stem cell lines produced & differentiatied at scale for allogeneic cell therapies for neuro-/cardio-/immunology/more | ph.1 trials |  | Tx | stem cells / allogeneic | PD, neuroDs, dAMD, HF | 3 | various cell types (see pipeline) | cell therapy | pharma | Seth Ettenberg | Boston, Toronto | public owner | $1,014 | 489 | 2016 | $225 | Bayer | bemdaneprocel | 2024-07-25 | 2020-01-05 | *Acquired by Bayer (remaining 59% for $600M) Aug'2019, but website still operating independently. Bemdaneprocel got RMAT designation from FDA for PD as of May'24. | 4.2 | 6.9 | 1.0 | 0.6 | 0.8 | 1.1 | 1.1 | 3.8 | 4.3 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||
40 | Glyscend | yes* | no | yes | yes | no | no | operating | pill to mimic bariatric surgery (polymer that coats duodenum) for T2D, obesity, & NAFLD/NASH | ph.2 trials | Tx | metabolism | T2D, obesity, NAFLD/NASH | 2 | duodenum lining | polymer drug | pharma | Sapan Shah | Boston | no | 15 | 2014 | $21.7 | paper & talk abstracts | 2024-08-22 | 2024-08-15 | *This counts as a calorie restriction mimetic. | 4.0 | 6.7 | 1.0 | 0.6 | 1.0 | 1.0 | 2.0 | 1.7 | 1.9 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
41 | InSilico Medicine | borderline* | yes | yes | yes | operating | AI for drug discovery platform with particular focus on aging diseases | ph.2 trials |  | Tx | broad platform | IPF, kidneyDs, cancer, Covid | 6 | TNIK, USP1, QPCTL, PHD, KAT6, 3CLpro | small molecules | pharma | Alex Zhavoronkov, Feng Ren | China, UAE, US, Canada | no | 268 | 2014 | $536 | 200+ papers | 2024-08-18 | 2019 | *Mostly AI for drug discovery (like many companies not focused on aging) but also consistently focused on aging: publishing on aging, launching aging-focused sites, creating aging partnerships,spinning off aging companies, sponsoring & organizing aging conferences, & having longevity as part of mission on homepage. | 4.0 | 5.7 | 0.5 | 0.7 | 1.0 | 1.1 | 2.2 | 3.5 | 3.9 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||
42 | Vandria | yes | yes | yes | yes | no | operating | tissue-specific small molecule mitophagy induction | pre-clinical |  | Tx | mitochondria | AD, PD, MCI, NASH, IPF, s-IBM | undisclosed; similar to urolithin A's? | small molecules | pharma | Klaus Dugi | Switzerland | no | 13 | 2021 | $32 | 2024-09-11 | 2024-08-26 | Hevolution (co-)led ~$30M series A round, Aug'24. | 3.9 | 4.3 | 1.0 | 0.9 | 1.0 | 1.1 | 0.6 | 1.6 | 2.2 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||
43 | Tranquis Therapeutics | yes | no | yes | yes | yes | operating | mitochondria & lysosome drugs to modulate myeloid immune cells via regulating PGC1α, autophagy, lysosome acidity; esp but not only for neuro diseases | ph.1 trials |  | Tx | mitochondria, autophagy | ALS, PD, AD, FTD, HD, MD, FA | 0 | PGC1α, lysosome acidity | small molecules | pharma | Frederic Godderis, Edgar Engleman | SF | no | 8 | 2016 | $30 | 1 pub, 2 presos | 2024-09-02 | 2022-06-29 | Last news from Aug'22 as of Sep'24. | 3.8 | 5.4 | 1.0 | 0.7 | 1.0 | 1.1 | 1.1 | 1.3 | 2.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
44 | Brainstorm Cell Therapeutics | only neuro | yes | yes | yes | no | yes | operating | autologous stem cells for neurodegeneration: MSCs differentiated to secret more neurotrophic factors (NTFs) | ph.3 trials |  | Tx | stem cells | ALS, MS, AD, PD, HD, ARDS, autism | 6 | cell therapy | pharma | Chaim Lebovits | Israel | yes | BCLI | $10 | 29 | 39 | 2004 | $63 | papers | 2024-09-28 | 2022-06-20 | Phase 3 trials for ALS completed as of 2024. | 3.8 | 4.2 | 0.5 | 0.9 | 1.0 | 1.1 | 3.3 | 2.3 | 1.5 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||
45 | Repair Biotechnologies | yes | yes | yes | yes | yes | yes | operating | reverse atherosclerosis by directly breaking down (catabolizing) excess free cholesterol, first via LNP delivery of mRNA | pre-clinical |  | Tx | intracell junk | hypercholesterolemia, MASH, atherosclerosis | free cholesterol | mRNA | pharma | Reason | Syracuse, NY | no | 8 | 2018 | $20 | 2024-09-04 | 2019 | 3.7 | 3.7 | 1.0 | 1.0 | 1.0 | 1.1 | 0.6 | 1.3 | 1.9 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||
46 | Vita Therapeutics | yes | no | yes | yes | no | yes | operating status | cell replacement of defective cells via autologous & allogeneic iPSC-derived genetically engineered cell therapy | pre-clinical |  | Tx | stem cells / autologous & allogeneic | muscular distrophies, cancer | 0 | cell therapy | pharma | Douglas Falk | DC | no | 20 | 2019 | $65.7 | papers | 2024-08-27 | 2024-08-15 | Cambrian sub-company. | 3.6 | 6.0 | 1.0 | 0.6 | 1.0 | 1.1 | 0.6 | 1.9 | 2.6 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
47 | Klotho Neurosciences | yes | yes | yes | yes | no | no | operating | novel truncated klotho variant via gene therapy or as recombinant protein biologic | pre-clinical |  | Tx | klotho | AD, PD, HD, CVD, KD | klotho | biologics, gene therapy / viral | pharma | Joseph Sinkule | yes | KLTO | $44 | 3 | 4 | 2019 | $3.1 | 2025-06-10 | 2025-06-10 | 3.4 | 3.8 | 1.0 | 0.9 | 1.0 | 1.1 | 0.6 | 0.9 | 2.4 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||
48 | Minovia Therapeutics | yes | yes | yes | no | no | yes | operating | placenta-derived allogeneic mitochondria for ex-vivo transplantation into stem cells (esp HSPCs), for mitochondrial diseases & aging | ph.1 trials |  | Tx | mitochondria, stem cells | Pearson, MDS, KSS, CAR-T | 7 | CD34+ HSPCs | cell therapy | pharma | Natalie Yivgi-Ohana | Israel | no | 30 | 2012 | $16.1 | Astellas | papers | 2024-08-15 | 2019 | 3.6 | 6.0 | 1.0 | 0.6 | 1.0 | 1.1 | 1.1 | 2.1 | 1.8 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||
49 | Alector | only neuro | yes* | yes | no | no | operating | combat neurodegeneration w/ genetics + immunology + neurology; esp modulate microglia w/ insights from plasma & CSF biomarkers & volumetric MRI | ph.3 trials |  | Tx | broad platform | FTD, AD, PD, LBD | 11 | progranulin, TREM2, GPNMB, GCase | pharma | SF | yes | ALEC | $155 | 244 | 269 | 2013 | $270 | GSK, Abbvie | many papers | 2024-07-31 | 2019 | *Mission is neurodegeneration, so within neuro-only focus, counts as aging since non-aging neuro indicatinos (TBI, genetic diseases) aren't a focus. | 3.6 | 5.9 | 0.5 | 0.6 | 1.0 | 1.1 | 3.3 | 3.5 | 3.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||
50 | LyGenesis | yes | no | yes | yes | no | yes | operating | allogeneic stem cells to use lymph nodes as in-vivo bioreactors to grow ectopic organs (eg liver, kidney, thymus, pancreas) instead of transplants | ph.2a trials |  | Tx | stem cells / allogeneic | liverDs, kidneyDs, T1D | 1 | hepatocytes engrafted to lymph nodes | cell therapy | pharma | Michael Hufford, Eric Lagasse | Pittsburgh | no | 6 | 2017 | $46 | liver 2; kidney 2 | 2024-08-01 | 2019 | Juvenencesce sub-company. | 3.6 | 6.0 | 1.0 | 0.6 | 1.0 | 1.1 | 1.5 | 1.1 | 2.4 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||
51 | Rejuvenation Technologies | yes | yes | yen | yes | yes | yes | operating | extend telomeres via nucleoside-modfied TERT mRNA lipid nanoparticles, in vitro & in vivo | pre-clinical |  | Tx | telomeres | (I)PF, COPD, CLD, BMF/cytopenia | telomerase | RNA | pharma | John Ramunas, Glenn Markov | SF | no | 20 | 2017 | $15.2 | papers | 2024-08-07 | 2019 | 3.5 | 5.0 | 1.0 | 0.7 | 1.0 | 1.1 | 0.6 | 1.9 | 1.7 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||
52 | New Limit | yes | yes | yes | yes | operating | epigenetic reprogramming discovery platform via single cell genomics, ML, & high-thru. func. assays to significantly extend healthspan, 1st for immune & liver | pre-clinical | Tx | epigenetic | pharma | Blake Byers, Brian Armstrong, Greg Johnson, Jacob Kimmel | SF | no | 29 | 2022 | $170 | 2024-08-05 | 2022-06-20 | Lots of details shared in the operating plan. | 3.5 | 5.8 | 1.0 | 0.6 | 1.0 | 1.0 | 0.5 | 2.1 | 3.2 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||||||
53 | Endogena Therapeutics | yes | no | yes | yes | no | yes | operating | drug discovery platform for small molecule regulators of endogenous stem/progenitor cells | ph.2a trials |  | Tx | stem cells | RP, dAMD, IPF | 1 | see paper | small molecules | pharma | Matthias Steger | Zurich | no | 7 | 2016 | $29 | only linked pub | 2024-08-04 | 2021-05-06 | Rejuveron sub-company. | 3.4 | 5.7 | 1.0 | 0.6 | 1.0 | 1.1 | 1.5 | 1.2 | 2.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||
54 | Deciduous Therapeutics | yes | yes | yes | yes | yes | operating | activate endogenous immune system mechanism to clear senescent cells | pre-clinical | Tx | senescence | IPF mentioned | iNKT cells | small molecules | pharma | Robin Mansukhani | SF | no | 16 | 2018 | $16.5 | key 2021 paper | 2024-08-03 | 2019 | May 2021 news article: https://www.statnews.com/2021/05/10/reawakened-immune-cells-show-promise-in-mice-against-senescent-cells/ | 3.4 | 4.8 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 1.7 | 1.8 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||
55 | Akero Therapeutics | yes | no | yes | no | no | no | operating | FGF21 mimetic, an engineered protein called efruxifermin (EFX) | ph.3 trials |  | Tx | metabolism | MASH | 6 | FGF21 | biologics | pharma | Andrew Cheng | SF | yes | AKRO | $4,126 | 60 | 67 | 2017 | 2024-11-23 | 2024-10-25 | 3.3 | 11.1 | 1.0 | 0.3 | 1.0 | 1.1 | 3.3 | 2.6 | 5.2 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||
56 | SENISCA | yes | yes | yes | yes | yes | operating | reverse cell senescence by modulation of RNA alternative splicing | pre-clinical | Tx | senescence, splicing | oligonucleotides | pharma | Sarah Cole, Lorna Harries, Ben Lee | Exeter, UK | no | 21 | 2020 | $11 | papers | 2024-09-03 | 2020-09-01 | 3.3 | 4.7 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 1.9 | 1.5 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||||||
57 | TNF Pharmaceuticals (was MyMD) | yes | yes | yes | no | no | no | operating | small molecule TNF-α inhibitor and synthetic CBD analog | ph.2 trials |  | Tx | inflammation | sarcopenia, RA, epilepsy | 3 | TNF-α | small molecules | pharma | Baltimore, MA | yes | TNFA | $2 | 6 | 10 | 2014 | $22 | papers | 2024-07-27 | 2023-06-01 | Raising more private money, new $14M w/ room for more as of May'24. Positive phase 2 data reported summer'23. | 3.0 | 5.1 | 1.0 | 0.6 | 1.0 | 1.1 | 2.2 | 1.4 | 0.6 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||
58 | Intervene Immune | yes | yes | yes | TBD* | yes | yes | operating | reverse thymus involution & immune aging via HGH + DHEA + metformin via human trials | ph.2 trials | Tx | stem cells | 1 | pharma / existing combos | Greg Fahy, Robert (Bobby) Brooke | LA | no | 6 | 2013 | $0.5 | a few on homepage | 2024-09-04 | 2019 | *Should affect multiple diseases, but not targeting any specific diseases clinically yet. | 3.1 | 4.0 | 1.0 | 0.8 | 1.0 | 1.0 | 2.0 | 1.1 | 0.2 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||||
59 | Epirium Bio | yes | no | yes | yes | no | operating | small molecule platform for muscle, regeneration, & mitochondria | pre-clinical |  | Tx | mitochondria | IPF, sarcopenia, SMA | 15-PGDH / PGE2 | small molecules | pharma | Russell Cox | SD | no | 16 | 2008 | $91 | 2024-09-01 | 2024-08-15 | 3.0 | 5.1 | 1.0 | 0.6 | 1.0 | 1.1 | 0.6 | 1.7 | 2.8 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||
60 | Ossium Health | yes | yes | no | no | yes | operating | allogeneic cell therapies from (deceased human donor) bone marrow for hematologic diseases, organ rejection & bone matrix allografts for musculoskeletal defects | ph.2 trials, commercial |  | Tx | stem cells / allogeneic | GVHD, multivisceral transplant, musculoskeletal defects | 9 | CD34+ cells | cell therapy | pharma | Kevin Caldwell, Erik Woods | SF, Indianapolis | no | 99 | 2016 | $137 | OssiGraft | papers | 2024-08-12 | 2024-08-12 | 2.9 | 9.7 | 1.0 | 0.3 | 1.0 | 1.1 | 2.2 | 2.9 | 3.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
61 | Thymmune Therapeutics | yes | yes | yes | no | yes | operating | iPSC thymus cell engineering/manufacturing platform generate to off-the-shelf (presumably allogeneic) cells at scale | pre-clinical | Tx | stem cells / allogeneic | cell therapy | pharma | Stan Wang | Boston | no | 21 | 2019 | $42 | 2024-10-16 | 2024-08-15 | Inejction into muscle & new thymic tissue develops there (so ectopic). | 2.8 | 4.7 | 1.0 | 0.6 | 1.0 | 1.0 | 0.5 | 1.9 | 2.3 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||||
62 | Rejuvenate Bio | yes | yes | yes | yes | no | no | operating | liver directed (combo) gene therapy for dogs & humans for age-related diseases | pre-clinical; vet clinical trials |  | Tx | metabolism and/or cell communication?, klotho | dogs: MVD, obesity, KF, OA; humans: ACM, HF, FPL, obesity, MASH | dogs, humans | FGF21, αKlotho, sTGFβR2, AAV | gene therapy | veterinary, pharma | Daniel Oliver, Noah Davidsohn, George Church | SD | no | 14 | 2017 | $19 | 2 at bottom | 2024-08-17 | 2019 | Not to be confused with Rejuvenate Biomed. | 2.8 | 3.1 | 1.0 | 0.9 | 1.0 | 1.1 | 1.7 | 1.6 | 1.8 | 1.0 | 0.5 | 1.2 | 0 | 1 | ||||||||||||||||||
63 | Shift Biosciences | yes | yes | yes | yes | yes | operating | reprogramming platform: AI/ML, custom single-cell transcriptomic aging clock, & wet lab tests to identify safe (max efficacy / least pluripotency) gene combos | pre-clinical | Tx | epigenetic | pharma | Daniel Ives | Cambridge, UK | no | 11 | 2017 | $22.5 | 2024-08-16 | 2019 | 2.8 | 4.0 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 1.5 | 2.0 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||||||
64 | Pluri Inc (prev Pluristem) | yes | no | yes | no* | no | yes | operating | placenta-derived allogeneic stem cell expansion platform, first for muscle, hematological conditions | ph.2 trials |  | Tx | stem cells / allogeneic | muscle injury, GVHD, radiation | 11 | placental derived stem cells | cell therapy | pharma | Yaky Yanay | Israel, Brazil | yes | PLUR | $39 | 123 | 183 | 2003 | $163 | papers | 2024-07-16 | 2022-06-29 | *Only muscle regen is really an aging diseases at present, but platform clearly has wider applicability so this will prob change to yes in future. | 2.79 | 9.3 | 1.0 | 0.3 | 1.0 | 1.1 | 2.2 | 3.2 | 2.3 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||
65 | GenFlow Biosciences | yes | yes | yes | yes | no | no | operating | gene therapies (AAV-based) for aging in dogs & humans, esp relating to SIRT6, inc a centenarian SIRT6 variant | pre-clinical*, vet pre-clinical |  | Tx | genomic | NASH/MASH, Werner, dog aging | dogs, humans | SIRT6 | gene therapy / AAV | pharma, veterinary | Eric Leire | London, Belgium | yes | GENF.L | $3 | 5 | 5 | 2020 | $1.3 | papers | 2024-09-04 | 2020-10-01 | *This page suggests they are close to starting phase 1. | 2.6 | 2.9 | 1.0 | 0.9 | 1.0 | 1.1 | 0.6 | 1.0 | 0.9 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||
66 | Tolerance Bio | yes | yes | yes | yes | operating | restore thymus w/ adult stem cell / iPSC derived thymic epithellial cell transplants & thymic organoids; also drugs | pre-clinical | Tx | stem cells | cell therapy, small molecules | pharma | Francisco Leon | SD | no | 10 | 2023 | $17.2 | papers | 2024-10-16 | 2024-10-16 | 2.69 | 4.5 | 1.0 | 0.6 | 1.0 | 1.0 | 0.5 | 1.4 | 1.8 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||||||
67 | Cleara Biotech | yes | yes | yes | yes | no | yes | operating | senolytics (esp vs 'scarred' SnCs), initially based on FOXO4, for healthspan & cancer, first for mutant-p53 cancer | pre-clinical |  | Tx | senescence | cancer, liverDs | p53 | peptides | pharma | Peter de Keizer | Netherlands | no | 13 | 2018 | $2.5 | 2024-09-04 | 2019 | 2.6 | 2.9 | 1.0 | 0.9 | 1.0 | 1.1 | 0.6 | 1.6 | 0.8 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||
68 | CellVie | yes | yes | yes | no | yes | operating | allogeneic mitochondria transplantation 1st for ischemia-reperfusion injury, esp arising via kidney transplant, then broader aging | pre-clinical | Tx | mitochondria | kidney transplant | cell/organelle therapy | pharma | Alex Schueller | Zurich, Switzerland | no | 11 | 2018 | $11 | 2024-09-05 | 2022-06-28 | Transplanted mitochondria enter cells via endocytosis & merged with the mito network. | 2.5 | 3.5 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 1.5 | 1.5 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||||
69 | MetroBiotech (International) | yes | yes | yes | no | no | operating | pharmaceutical NAD+ precursors & enhancers | ph.2 trials | Tx | mitochondria / NAD+ | T2D, diabetic kidney disease, Covid, FA | 4 | pharma | David Livingston, David Sinclair* | no | 9 | 2014 | unknown | mix from company +external | 2024-09-03 | 2024-08-15 | *David Sinclair is often mentioned as a founder & SAB member, and lists the company on his LinkedIn page (thru 'present'), but he's not currently listed on the company website as of Sep'24. | 2.4 | 4.0 | 1.0 | 0.6 | 1.0 | 1.0 | 2.0 | 1.4 | 0.0 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||||
70 | Morphoceuticals Inc | yes | yes | yes | no | yes | operating | bioelectrics, together with multi-omics & AI, for tissue repair and organ regeneration | pre-clinical | Tx | stem cells* | pharma | Jim Jenson, Michael Levin | Boston | no | 6 | 2020 | $14.5 | papers | 2024-10-18 | 2021-05-12 | *Not based on stem cells, but "stem cells" is the categorical term used on this site for regenerative med (replentishing cell loss), which is the best-fit category for this company. Juvenescence sub-company. | 2.4 | 4.0 | 1.0 | 0.6 | 1.0 | 1.0 | 0.5 | 1.1 | 1.7 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||||||
71 | ImmuneAGE Bio | yes | yes | yes | yes | yes | yes | operating | immune system rejuvenation drug platform via 1000x HSC expansion enabling screening & better BMT; also mitophagy & mitochondria biogenesis small molecule | pre-clinical |  | Tx | stem cells, mitochondria | ARIs, BMT (MM), HSC banking (pre-chemo) | similar to Urolithin A's? (source)* | small molecules, cell therapy | pharma | Sebastian A. Bunemeier | no | 6 | 2022 | $2 | 2024-09-11 | 2024-08-15 | *Also a patent here. | 2.3 | 2.3 | 1.0 | 1.0 | 1.0 | 1.1 | 0.6 | 1.1 | 0.7 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||
72 | GenSight Biologics | yes* | no | yes | no | no | yes | operating | allotopic expression of mito gene ND4 in nucleus w/ mRNA delivery to mito membrane; also optogenetics system; for retinal diseases via AAV gene therapy | ph.3 trials |  | Tx | mitochondria | LHON, RP, dAMD | 9 | mito ND4 gene | gene therapy / viral | pharma | Laurence Rodriguez | Paris, NYC | yes | SIGHT.PA | $18 | 16 | 38 | 2012 | $264 | LUMEVOQ | 2024-07-26 | 2019 | *Allotopic expression of mtDNA w/ mito delivery could rescue general mito aging. This is farthest along allotopic exp clin prog tho for genetic disease. Had notable ph.3 fails 2018-19 inc unusual fail due to improved vision in control eye. Now pursuing new ph.3 involving treating both eyes. | 2.2 | 7.4 | 1.0 | 0.3 | 1.0 | 1.1 | 3.3 | 2.3 | 1.8 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||
73 | Revel Pharmaceuticals | yes | yes | yes | yes | yes | operating | platform for designing enzymes to repair drivers of aging & disease: accumulation of toxic proteins or metabolites esp. AGEs | pre-clinical | Tx | ECM | RA | CML, citrulline, glucosepane, carbamylation | enzymes | pharma | Aaron Cravens | SF | no | 7 | 2019 | $10.7 | 2024-08-20 | 2019 | 16min presentation at 2024 Rejuvenation Startup Summit in Berlin. | 2.3 | 3.2 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 1.2 | 1.5 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||
74 | Lineage Cell Therapeutics | yes | no | yes | no | no | yes | operating | allogeneic transpalntation of cells terminally differentiated f/ reproducible pluripotent stem cells | ph.2 trials |  | Tx | stem cells / allogeneic | dry AMD, SCI, hearing loss | 2 | RPE cells, OPCs | cell therapy | pharma | SD | yes | LCTX | $228 | 68 | 32 | 1990 | $109 | Genentech | OpRegen | 2024-07-27 | 2022-09-23 | 2.3 | 7.7 | 1.0 | 0.3 | 1.0 | 1.1 | 2.2 | 2.2 | 3.4 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||
75 | Transposon Therapeutics | only neuro | yes | yes | TBD | yes | no | operating | nucleoside inhibitors of LINE-1 reverse transcriptase (NRTIs) & other LINE-1 modulation (eg Protein Kinase R inhibitors, PKRs) for neurodegenerative diseases | ph.2 trials* |  | Tx | genomic | PSP, ALS, FTD, AGS, AD | 3 | LINE-1 | small molecules | pharma | Dennis Podlesak | SD | no | 5 | 2019 | $59.12 | censavudine | 2024-08-12 | 2024-08-12 | *Final results press release announcement from phase 2 trial for ALS, Jul'24. | 2.2 | 2.9 | 0.5 | 0.8 | 1.0 | 1.1 | 2.2 | 1.0 | 2.5 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||
76 | Neuraly | only neuro | yes* | yes | no | no | operating | neurodegeneration 1st via GLP-1R agonist that targets microglia/astrocytes-induced neuroinflammation w/ preclinical efficacy in PD & AD models | ph.2 trials |  | Tx | inflammation? | PD, AD, stroke | 5 | GLP-1 (in microglia/ astrocytes) | small molecules? | pharma | Seulki Lee, Ted Dawson, Viktor Roschke | DC | no | 16 | 2016 | $36 | papers (at bottom) | 2024-08-20 | 2024-08-15 | *Mission is neurodegeneration, so within neuro-only focus, counts as aging since non-aging neuro indicatinos (TBI, genetic diseases) aren't a focus. Subsidiary of D&D Pharmatech | 2.2 | 3.7 | 0.5 | 0.6 | 1.0 | 1.1 | 2.2 | 1.7 | 2.2 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||
77 | Covalent Bioscience | yes | yes | yes | yes | no | yes | operating | catalytic antibodies (catabodies) for aging (1st for ATTR, Aβ, & tau) & electrophilic vaccines (1st for HIV) | pre-clinical | Tx | proteostasis | CVD, AD, HIV | ATTR, Aβ, tau | biologics | pharma | Houston | no | 4 | 2011 | $2.0 | papers | 2024-10-04 | 2019 | Feb'24 article suggests current activity & seeking funding, but "recent news" page on website has no news since Jun'19. | 2.2 | 2.5 | 1.0 | 0.9 | 1.0 | 1.0 | 0.5 | 0.9 | 0.7 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||
78 | Klotho Therapeutics | yes | yes | yes | yes | no | no | operating | recombinant klotho | pre-clinical | Tx | klotho | neuroDs, kidneyDs, cancer, diabetes | klotho | biologics | pharma | no | 2 | 2016 | $10 | 2024-07-29 | 2024-07-29 | 2.2 | 2.4 | 1.0 | 0.9 | 1.0 | 1.0 | 0.5 | 0.4 | 1.5 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||||
79 | Ponce Therapeutics | yes | yes | yes | yes | no | yes | operating | 2 senolytics for epithelial & mesenchymal SnCs & SASP-suppressing tyrosine kinase inhibitor senomorphics | pre-clinical |  | Tx | senescence | wrinkles, cataracts | Caspase-9; JAK2/3//TYK2 | peptides, small molecules? | pharma | Kevin Slawin | Houston | no | 8 | 2019 | $1.5 | 2024-08-23 | 2024-08-23 | Both topical (skin) & systemic programs. Not to be confused with Ponce de Leon Health (Rejuvant) | 2.2 | 2.4 | 1.0 | 0.9 | 1.0 | 1.1 | 0.6 | 1.3 | 0.6 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||
80 | HCW Biologics | yes* | yes | yse | no | no | yes | operating | immune platform to disrupt inflammaging: rejuvenate immune sys, clear senescent cells, & modulate inflammasomes via multi-/bispecific fusion proteins | ph.2 trials |  | Tx | inflammation, senescence | cancer, autoimmune, infectious | 2 | TGF-β, IL-15, IL-2, IL-7, IL-21 | biologics | pharma | Hing C. Wong | Miami | yes | HCWB | $9 | 45 | 29 | 2018 | $68 | papers; posters | 2024-08-18 | 2024-08-15 | *Lead indication is cancer but they think lead asset also has dual senescence MoA: clears senescent cells & modulates SASP. See 2023 paper in Aging Cell & this page. 2024 settled lawsuit giving ImmunityBio rights to lead HCW9218 for some cancer indications but HCWB retains "exclusive worldwide rights [..] HCW9218 for aging-related diseases other than cancer." | 2.1 | 6.8 | 1.0 | 0.3 | 1.0 | 1.1 | 2.2 | 2.1 | 1.4 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||
81 | MitoRX Therapeutics | yes* | no | yes | yes | no | no | operating | mitochondria small molecules regulating sulfide-signaling: substrate replenishment for trans-sulfuration deficiency | pre-clinical |  | Tx | mitochondria | DMD, obesity, COPD, HD, AD, PD, CBS-def, CMT2A | small molecules | pharma | Jon Rees, Matt Whiteman | London, Oxford, UK | no | 14 | 2021 | $6.9 | 2024-09-01 | 2024-08-15 | *Rare mito diseases are initial focus, but technology applicable to neurodegeneration & mito aging broadly. | 2.1 | 3.5 | 1.0 | 0.6 | 1.0 | 1.1 | 0.6 | 1.6 | 1.3 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||
82 | Longevity Biotech | yes* | no | yes | yes | no | no | operating | synthetic orally available peptide platform, esp for neuroinflammatory diseases | ph.1 trials |  | Tx | inflammation, metabolism | PD, neuroinflammation, diabetes, cancer | 2 | B-GPCR, VIP, GLP-1, GIP | peptides | pharma | Scott Shandler | Philadelphia | no | 6 | 2010 | $1.9 | several | 2024-09-03 | 2019 | *Longevity in company name refers to stability of the peptides, not longevity of the patient. Nonetheless, the targets/MoAs include age related areas of neuroinflammation & nutrient sensing, plus all indications are age-related diseases as of Sep'24, despite that aging/longevity doesn't seem to be a company focus. | 2.1 | 3.4 | 1.0 | 0.6 | 1.0 | 1.1 | 1.1 | 1.1 | 0.7 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||
83 | Samsara Therapeutics | only neuro | yes | yes | yes | no | no | operating | small molecule autophagy activators screening platform via iPSC testing for neurodegeneration | pre-clinical |  | Tx | autophagy | neuroDs | TDP-43, α-synuclein, PMP-22 | small molecules | pharma | Oxford, UK | no | 23 | 2018 | $25 | 2024-08-02 | 2019 | Not to be confused with public software company Samsara. | 2.0 | 2.3 | 0.5 | 0.9 | 1.0 | 1.1 | 0.6 | 1.9 | 2.0 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||
84 | Fauna Bio | yes* | no* | yes | yes | operating | comparative animal genomics & multi-omics for drug discovery biased to human druggable targets to generally improve human health inc. longevity areas | pre-clinical | Tx | broad platform | ** (see notes) | pharma | Ashley Zehnder, Katie Grabek, Linda Goodman | SF | no | 28 | 2018 | $13 | pubs at bottom | 2024-07-28 | 2019 | *Central idea & mission phrased more generally for human health in any area but many lead areas specifically important in aging & longevity mentioned explicitly as an area in a few places ** Takes inspiration/bio from other species but target species is still humans. | 2.0 | 5.1 | 1.0 | 0.4 | 1.0 | 1.0 | 0.5 | 2.1 | 1.7 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||||||
85 | Pretzel Therapeutics | yes* | no | yes | no | no | operating | upregulate mtDNA for mitochondria health, 1st for genetic mitochondria diseases but also for age-related conditions | pre-clinical | Tx | mitochondria | pharma | Jay Parrish | Sweden, Boston | no | 49 | 2019 | $73 | papers | 2024-09-10 | 2024-08-15 | *Assuming yes based on generality of potential of upregulation of mtDNA, but if the company never goes beyond genetic mitochondria diseases, it may eventually be moved off of this list. | 2.0 | 6.7 | 1.0 | 0.3 | 1.0 | 1.0 | 0.5 | 2.4 | 2.7 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||||||
86 | Casma Therapeutics | yes | no | yes | no | no | no | operating | drug platform (using heterobifunctional chemistry) for modulating autophagy as a form of targeted degradation (autophagosome biogenesis around the target) | pre-clinical |  | Tx | autophagy | cancer, PD | TRPML1 | drugs | pharma | Frank Gentile | Boston | no | 18 | 2018 | $183 | select type = pub | 2024-08-20 | 2023-05-29 | 2.0 | 6.7 | 1.0 | 0.3 | 1.0 | 1.1 | 0.6 | 1.8 | 3.2 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||
87 | Amplifier Therapeutics | yes | yes | yes | no | operating | AMPK activators | ph.1b trials* |  | Tx | metabolism | cardiometabolic diseases | 0* | AMPK | small molecules? | pharma | James Hall | no | 0 | 2022 | $33 | 2024-11-18 | 2024-08-15 | *Cambrian website pipeline image shows ph.1/2a for ATX-304 & Amplifier website pipeline shows just ph.2 but can't find trial on clinicaltrials.gov under either company name or ATX-304 as of Jul'24 so using press release of 1b as current clinical stage as of Aug'24. Cambrian sub-company. | 2.0 | 3.3 | 1.0 | 0.6 | 1.0 | 1.1 | 1.1 | 0.0 | 2.2 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||
88 | Arda Therapeutics | yes | yes | yes | yes | operating | killing pathogenic cells for chronic diseases & aging via single-cell data to identify bad cells & how to target them, then very targeted elimination | pre-clinical | Tx | pharma | Adam Freund | SF | no | 9 | 2021 | $8.5 | 2024-09-01 | 2024-08-15 | 2.0 | 3.3 | 1.0 | 0.6 | 1.0 | 1.0 | 0.5 | 1.4 | 1.4 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||||||||
89 | Timeline | yes | yes | yes | yes | no | no | operating | nutraceutical MitoPure, a pure Urolithin A for mitochondria health (upregulates mitophagy) | commercial, ph.2 trials | Tx | mitochondria | frailty/sarcopenia, wrinkles/skin-aging, COPD | 17 | Urolithin A's targets/MoA (↑mitophagy) | supplements | nutraceuticals | Switzerland | no | 47 | 2007 | $80.3 | CHf64.4 | MitoPure | papers | 2024-09-03 | 2022-06-30 | Results of immune trial announced May'24. Formerly called Amazentis (or that might still be a corporate parent company). | 1.9 | 2.1 | 1.0 | 0.9 | 1.0 | 1.0 | 2.0 | 2.4 | 2.7 | 1.0 | 0.3 | 1.2 | 0 | 1 | ||||||||||||||||||
90 | Praetego | yes | yes | yes | yes | no | no | operating | class of BBB-penetrant small molecules (Amadorins) that inhibit AGEs, esp for neurodegeneration, esp AD | pre-clinical | Tx | ECM | AD, DPN, DR | small molecules | pharma | Pepper Landson | no | 2 | 2017 | $5.9 | 2024-09-04 | 2024-08-15 | 1.9 | 2.1 | 1.0 | 0.9 | 1.0 | 1.0 | 0.5 | 0.4 | 1.2 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||||||
91 | Cyclarity (was Underdog) | yes | yes | TBD | no | TBD | yes | operating | cyclodextrin derivatives to remove 7-ketocholesterol to remove arterial plaques | pre-clinical | Tx | intracell junk | atherosclerosis, heart attack, stroke | 7-ketocholesterol (7KC) | drugs | pharma | Matthew ‘Oki’ O’Connor, Michael Kope | SF | no | 14 | 2019 | $18 | 2021; 2020 | 2024-08-02 | 2019 | 1.9 | 4.7 | 1.0 | 0.4 | 1.0 | 1.0 | 0.5 | 1.6 | 1.8 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||
92 | Booster Therapeutics | yes | yes | yes | no | operating | small molecules to boost the activity of 20S proteosomes (whose activity declines with age) for proteostasis | pre-clinical | Tx | proteostasis | 20S proteosome | small molecules | pharma | Diogo R. Feleciano | no | 4 | 2020 | $15 | 2024-10-21 | 2024-10-17 | Apollo VC invested. | 1.9 | 3.1 | 1.0 | 0.6 | 1.0 | 1.0 | 0.5 | 0.9 | 1.7 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||||||
93 | Cyclo Therapeutics | borderline* | no | yes | no | no | yes? | operating | hydroxypropyl beta cyclodextrin for cholesterol transport, first for AD & Niemann-Pick | ph.3 trials |  | Tx | intracell junk | Niemann Pick, AD | 6 | cholesterol | drugs | pharma | N. Scott Fine | Gainesville, FL | yes | CYTH | $4,647 | 8 | 18 | 1990 | $17 | Trappsol Cyclo | papers | 2024-08-02 | 2022-06-01 | *Yes tentatively based on likely breadth of platform applicability. | 1.9 | 6.2 | 0.5 | 0.3 | 1.0 | 1.1 | 3.3 | 1.8 | 5.2 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||
94 | Elastrin Therapeutics | yes | no | yes | yes | yes | operating | drug plattform for damaged elestin: nanoparticle with drug + elastin antibody for targeting | pre-clinical | Tx | ECM | Marfan, COPD, cardiovascularDs | elastin | pharma | Naren Vyavahare | Greenville, SC | no | 9 | 2017 | $21 | papers | 2024-09-04 | 2022-06-28 | 1.8 | 4.5 | 1.0 | 0.4 | 1.0 | 1.0 | 0.5 | 1.4 | 1.9 | 1.0 | 1.0 | 1.2 | 0 | 1 | |||||||||||||||||||||||
95 | Vincere Biosciences | yes | yes | yes | yes | operating | small molecule mitophagy upregulation, esp for PD, via USP30 inhibition or Parkin activation | pre-clinical | Tx | mitochondria | PD, kidneyDs? | USP30, Parkin | small molecules | pharma | Spring Behrouz, Andy Lee | Boston | no | 10 | 2018 | $1.8 | 2024-09-07 | 2024-08-15 | Talks by & on the company abound, eg 2024 Dublin Longevity Summit. Spun out of NeuroInitiative. | 1.8 | 2.6 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 1.4 | 0.6 | 1.0 | 1.0 | 1.0 | 0 | 1 | |||||||||||||||||||||||
96 | Renewal Bio | yes | yes | yes | yes | yes | operating | "renew humanity - making all of us young and healthy" | pre-clinical | Tx | stem cells* | pharma? | Israel | no | 14 | 2022 | unknown | 2021 paper 2022 paper | 2023-05-27 | 2023-05-29 | *Replacement cell/organ source technology company, including as stem cell source but also replacement tissue/organs. "Stem cells" is the categorical term used on this site for regenerative med (replentishing cell loss) even if not based on stem cells. | 1.8 | 2.6 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 1.6 | 0.0 | 1.0 | 1.0 | 1.2 | 0 | 0 | |||||||||||||||||||||||||
97 | GEn1E Lifesciences | yes | no | yes | no | no | no | operating | drug discovery platform for inflammatory diseases, lead is p38α kinase inhibitor | ph.2 trials |  | Tx | inflammation | ARDS | 2 | p38α:MK2, ERK 1/2 | drugs | pharma | SF | no | 15 | 2018 | $17 | 2024-08-03 | 2019 | *Website doesn't really talk about aging, just inflammation, but main target p38 clearly age related. | 1.7 | 5.7 | 1.0 | 0.3 | 1.0 | 1.1 | 2.2 | 1.7 | 1.8 | 1.0 | 1.0 | 1.0 | 0 | 1 | ||||||||||||||||||||
98 | ChromaDex | yes | yes | yes | yes | no* | no | operating | nutraceuticals for aging, esp. Tru Niagen w/ nicotinamide riboside (NR), an NAD+ precursor | commercial, ph.4 trials | Tx | mitochondria / NAD+ | cancer, MCI, HF, mitoDs, more... | 43 | NAD+ | supplements | nutraceuticals | Robert Fried, Charles Brenner | LA | yes | CDXC | #N/A | 106 | 129 | 1999 | $85 | Tru Niagen | papers | 2024-07-16 | 2019 | *Charles Brenner attends a few conferences but more as a scientist than company rep & not the execs or company as sponsor/presenter. | 1.7 | 1.9 | 1.0 | 0.9 | 1.0 | 1.0 | 0.5 | 3.0 | 2.8 | 1.0 | 0.3 | 1.2 | 0 | 1 | |||||||||||||||
99 | Mitrix | yes | yes | yes | yes | yes | operating | mitochondria transplant of bioreactor-grown "young" mitochondria | pre-clinical | Tx | mitochondria | cell/organelle therapy | pharma | Tom Benson | SF | no | 9 | 2018 | $0.3 | papers | 2024-09-07 | 2019 | 1.7 | 2.4 | 1.0 | 0.7 | 1.0 | 1.0 | 0.5 | 1.4 | 0.1 | 1.0 | 1.0 | 1.2 | 0 | 1 | ||||||||||||||||||||||||
100 | Cerevance | only neuro | no | yes | no | no | operating | drug discovery platform based on sequencing of post-mortem human brain tissue: transcriptome diffs by age, cell type, region, & disease | ph.3 trials |  | Tx | broad platform | PD, AD, ALS, obesity | 10 | GPR6, Ox1R, KCNK13, THIK-1 | small molecules | pharma | Cambridge, UK | no | 61 | 2016 | $204 | Solengepras | papers | 2024-09-20 | 2019 | 1.6 | 5.5 | 0.5 | 0.3 | 1.0 | 1.1 | 3.3 | 2.6 | 3.3 | 1.0 | 1.0 | 1.2 | 0 | 1 |